Allosteric interactions at adenosine A1 and A3 receptors: New insights into the role of small molecules and receptor dimerization

Stephen J Hill, Lauren Therese May, Barrie Kellam, Jeanette Woolard

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specific GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs-protein-coupled adenosine receptors (A2A and A2B), or inhibit AC activity, in the case of Gi/o-coupled adenosine receptors (A1 and A3). Recent advances in our understanding of GPCR structure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosine A1 and A3 receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single-cell ligand-binding kinetics and the effects of A 1- and A3-receptor allosteric modulators on in vivo pharmacology.
Original languageEnglish
Pages (from-to)1102 - 1113
Number of pages12
JournalBritish Journal of Pharmacology
Volume171
Issue number5
DOIs
Publication statusPublished - 2014

Cite this

@article{7066f7ede44b487ab6aac0288aaf7f59,
title = "Allosteric interactions at adenosine A1 and A3 receptors: New insights into the role of small molecules and receptor dimerization",
abstract = "The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specific GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs-protein-coupled adenosine receptors (A2A and A2B), or inhibit AC activity, in the case of Gi/o-coupled adenosine receptors (A1 and A3). Recent advances in our understanding of GPCR structure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosine A1 and A3 receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single-cell ligand-binding kinetics and the effects of A 1- and A3-receptor allosteric modulators on in vivo pharmacology.",
author = "Hill, {Stephen J} and May, {Lauren Therese} and Barrie Kellam and Jeanette Woolard",
year = "2014",
doi = "10.1111/bph.12345",
language = "English",
volume = "171",
pages = "1102 -- 1113",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "5",

}

Allosteric interactions at adenosine A1 and A3 receptors: New insights into the role of small molecules and receptor dimerization. / Hill, Stephen J; May, Lauren Therese; Kellam, Barrie; Woolard, Jeanette.

In: British Journal of Pharmacology, Vol. 171, No. 5, 2014, p. 1102 - 1113.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Allosteric interactions at adenosine A1 and A3 receptors: New insights into the role of small molecules and receptor dimerization

AU - Hill, Stephen J

AU - May, Lauren Therese

AU - Kellam, Barrie

AU - Woolard, Jeanette

PY - 2014

Y1 - 2014

N2 - The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specific GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs-protein-coupled adenosine receptors (A2A and A2B), or inhibit AC activity, in the case of Gi/o-coupled adenosine receptors (A1 and A3). Recent advances in our understanding of GPCR structure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosine A1 and A3 receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single-cell ligand-binding kinetics and the effects of A 1- and A3-receptor allosteric modulators on in vivo pharmacology.

AB - The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specific GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs-protein-coupled adenosine receptors (A2A and A2B), or inhibit AC activity, in the case of Gi/o-coupled adenosine receptors (A1 and A3). Recent advances in our understanding of GPCR structure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosine A1 and A3 receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single-cell ligand-binding kinetics and the effects of A 1- and A3-receptor allosteric modulators on in vivo pharmacology.

UR - http://onlinelibrary.wiley.com/doi/10.1111/bph.12345/pdf

U2 - 10.1111/bph.12345

DO - 10.1111/bph.12345

M3 - Article

VL - 171

SP - 1102

EP - 1113

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 5

ER -